Balyasny Asset Management
FBRX

Balyasny Asset Management’s Forte Biosciences FBRX Stock Holding History

Balyasny Asset Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$827K Buy
38,898
+20,181
+108% +$479K ﹤0.01% 2313
2026
Q1 		$485K Buy
+18,717
New +$539K ﹤0.01% 2382

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Balyasny Asset Management's FBRX Position: Q2 2026 in Review

Balyasny Asset Management increased its Forte Biosciences (FBRX) stake by 108% in Q2 2026, buying an estimated $479K and bringing the position to 38,898 shares worth $827K. The position accounts for ﹤0.01% of the portfolio, ranked #2313.

Balyasny Asset Management first reported a position in FBRX in Q1 2026 and has held it in 2 quarters since. 86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Balyasny Asset Management held 38,898 shares of Forte Biosciences worth $827K as of Q2 2026.
  • Balyasny Asset Management bought 20,181 Forte Biosciences shares in Q2 2026, an estimated $479K.
  • Forte Biosciences made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #2313 holding.
  • Balyasny Asset Management first reported a position in Forte Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.